Topics / Hematology

Weekly issue

Hematology Papers of the Week

The top Hematology papers of the week: the 20 most important new papers of the past week, ranked by potential impact. A new issue comes out every Monday, covering the previous Monday-to-Sunday week.

Nov 9 - 15, 2026 · Updated

Prefer new papers every day? It's free.Daily Hematology Papers →
  1. 1
  2. 2
  3. 3
    CD19-CD28 Costimulatory Bispecific Antibody Plus Glofitamab in R/R B-NHL: A Phase 1 Dose-escalation Study

    In this study, 52 patients with heavily pre-treated B-NHL (aggressive, n = 33; indolent, n = 19) received obinutuzumab pretreatment to mitigate cytokine release syndrome, glofitamab step-up dosing (2.5/10/30 mg), and the addition of CD19-CD28 (initiated on cycle 1 day 10 or cycle 2 day 8), for up to 12 cycles.

  4. 4
    Tumor Cells Hijack Coagulation Signaling to Enable Immune Escape and Metastatic Dissemination

    Here, we identified the coagulation initiator tissue factor (F3) as a central regulator bridging tumor metastasis and immune evasion in gastric cancer (GC).

  5. 5
    CD3scFv-Engineered AAV Capsid Drives Superior In Vitro and In Vivo CAR-T Cell Generation and Leads to Complete Eradication of CD19+ Tumors

    In vivo, a single intravenous dose of AVO-100 at 2×10 vector genomes (vg) per subject using NSG mice bearing Raji xenografts, prompted complete tumor eradication and significantly prolonged survival, whereas control untreated animals succumbed to a progressive disease. These results demonstrate that site-selective CD3scFv insertion into a single AAV capsid protein provides a robust, versatile platform for improved T cell transduction and effective in vivo CAR-T cell generation, offering a promising off-the-shelf approach for treating B cell malignancies.

Get papers like these the day they come out, not a week later.

Follow this category
  1. 6
    Risk-Adapted Donor Selection in Patients with Acute Myeloid Leukemia

    We applied a doubly robust strategy combining multinomial propensity-score inverse probability of treatment weighting (IPTW) with multivariable Cox and Fine-Gray regression.

  2. 7
  3. 8
    Cas12a-based Combinatorial Knockout Screens Define The Genetic Architecture of The DNA Damage Response

    To elucidate the genetic architecture of the DNA damage response (DDR) network, we conduct unbiased genetic interaction screens using Cas12a.

  4. 9
    Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure

    We analyzed 11 340 patients and identified 418 BCOR/L1-mutated patients, focusing on differences between MN and BMF.

  5. 10
  6. 11
  7. 12
  8. 13
    Final Analysis of The BRUIN Phase 1/2 Study Assessing The Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

    Here, we report final results from the global Phase 1/2 BRUIN trial evaluating pirtobrutinib in patients with R/R MCL, with and without prior cBTKi exposure.

  9. 14
  10. 15
    Terminal Differentiation Program of CD8 T Cells Guides Immunotherapeutic Options for CLL Patients

    Here, we performed an integrated phenotypic, epigenetic and functional analysis of circulating CD8⁺ T cells from treatment-naive CLL patients to define the nature and therapeutic relevance of terminal differentiation in CLL.

  11. 16
    Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of The BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials

    To better characterize the therapeutic benefits of the addition of carboplatin to anthracycline- and taxane-based neoadjuvant chemotherapy (NACT) in early-stage triple-negative breast cancer (TNBC), we performed a pooled analysis of three randomized clinical trials: BrighTNess (NCT02032277), CALGB 40603 (NCT00861705), and GeparSixto (NCT01426880).

  12. 17
    Antigen Scaffolds Drive Preferential Expansion of Functional Genetically Engineered CAR and TCR T Cells

    However, manufacturing is resource intensive and often yields highly differentiated, exhausted T cell products. To address this, we developed an antigen-scaffold (Ag-scaffold) technology that presents cognate antigen alongside stimulatory cytokines to preferentially expand genetically engineered T cells.

  13. 18
    Associations Between Biomarkers of Vitamin K and Cardiovascular Disease Risk Factors: The Role of Lipids

    We investigated the associations between levels of circulating vitamin K vitamers, phylloquinone (PK) and total menaquinones (MK), and dephospho-undercarboxylated matrix Gla protein (dp-ucMGP, a biomarker of functional vitamin K status), with multiple cardiovascular disease risk factors and adjusted for triglycerides.

  14. 19
    Impact of Venetoclax-based Therapies on CLL-associated Autoimmune Cytopenias: A Retrospective Study Conducted By ERIC

    This study aimed to evaluate preexisting and treatment-emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax-based combinations. In this retrospective multicenter study, data from 1720 patients were collected; 23.1% received venetoclax single agent and 76.9% venetoclax combinations (mostly containing anti-CD20 monoclonal antibodies and/or BTK inhibitors).

  15. 20
    Monoclonal Gammopathy of Neurologic Significance: A Practical Framework for Diagnosis and Management

    This review presents a practical, stepwise diagnostic and therapeutic framework for MGNS, emphasizing multidisciplinary collaboration between hematology and neurology.